Literature DB >> 25221744

Risk stratification and mitigation multiple sclerosis.

Daniel Ontaneda, Samuel Cohn, RobertJ Fox.   

Abstract

The increasing availability of new agents to treat multiple sclerosis poses new challenges for clinicians who seek therapies that are both safe and effective for their patients. The introduction of additional effective therapies has been accompanied by the recognition of serious side effects. The clinician now must weigh both the benefits and risks of therapies to help patients decide which treatment best fits each patient׳s risk/benefit profile. An optimal selection of therapies relies on a complete understanding of the risks of therapies and the factors that may help evaluate and mitigate those risks. An individualized treatment approach that incorporates patient and disease factors is needed for each patient. In this review we present risk stratification and mitigation strategies of disease modifying agents for multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25221744      PMCID: PMC4159169          DOI: 10.1016/j.msard.2014.05.003

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  72 in total

1.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

2.  Effect of Campath-1H antibody on human hematopoietic progenitors in vitro.

Authors:  M H Gilleece; T M Dexter
Journal:  Blood       Date:  1993-08-01       Impact factor: 22.113

3.  PML in a patient treated with fumaric acid.

Authors:  Ummehan Ermis; Joachim Weis; Jörg B Schulz
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

4.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

5.  Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.

Authors:  M P Sormani; D K Li; P Bruzzi; B Stubinski; P Cornelisse; S Rocak; N De Stefano
Journal:  Neurology       Date:  2011-10-05       Impact factor: 9.910

6.  A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

Authors:  R Zivadinov; J Sepcic; D Nasuelli; R De Masi; L M Bragadin; M A Tommasi; S Zambito-Marsala; R Moretti; A Bratina; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

Review 7.  Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.

Authors:  Suhayl Dhib-Jalbut
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

8.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

9.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  4 in total

Review 1.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

2.  Effect of an Educational Intervention on Therapeutic Inertia in Neurologists With Expertise in Multiple Sclerosis: A Randomized Clinical Trial.

Authors:  Gustavo Saposnik; Marcus Grueschow; Jiwon Oh; Maria A Terzaghi; Pawel Kostyrko; Shruthi Vaidyanathan; Rosane Nisenbaum; Christian C Ruff; Philippe N Tobler
Journal:  JAMA Netw Open       Date:  2020-12-01

Review 3.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711

4.  Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS).

Authors:  Gustavo Saposnik; Angel Perez Sempere; Roula Raptis; Daniel Prefasi; Daniel Selchen; Jorge Maurino
Journal:  BMC Neurol       Date:  2016-05-04       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.